IL17A and psoriasis vulgaris: While systemic antibody-based cytokine neutralization strategies targeting IL-1, IL-17, and IL-17/23 have greatly improved therapeutic outcomes for patients with severe plaque psoriasis, such therapies are costly and can be associated with serious side effects30,31.